Vaccine trial for Leukemia
According to today's newspaper, yet another cancer vaccine trial is in the offing.
This one is for Acute myeloid leukemia (AML), which is the most common form of Leukemia in adults. The disease returns in about half of patients following therapy ... i.e., marrow transplant and chemo.
The trial is taking place at King's College in London, England.
Cells are given two genes to identify the leukemia. This increases the immune system’s ability to attack cancer cells. The research is expected to be published in the Journal of Cancer Immunology, Immunotherapy in 2011.
Let's wish them well. If successful, this therapy will likely be investigated in other types of blood cancer.
Study leaders are Ghulam Mufti, Farzin Farzaneh and Dr. Nicola Hardwick at University College London. They have developed a virus which carries the two genes into the immune system.
This one is for Acute myeloid leukemia (AML), which is the most common form of Leukemia in adults. The disease returns in about half of patients following therapy ... i.e., marrow transplant and chemo.
The trial is taking place at King's College in London, England.
Cells are given two genes to identify the leukemia. This increases the immune system’s ability to attack cancer cells. The research is expected to be published in the Journal of Cancer Immunology, Immunotherapy in 2011.
Let's wish them well. If successful, this therapy will likely be investigated in other types of blood cancer.
Study leaders are Ghulam Mufti, Farzin Farzaneh and Dr. Nicola Hardwick at University College London. They have developed a virus which carries the two genes into the immune system.
posted by gwg at 3:46 PM
0 Comments:
Post a Comment
<< Home